IFF Heads Into Q3 Print With Analysts Turning More Bullish

IFF reports Q3 results on November 3 with analyst sentiment clearly moving in one direction heading into the print.

The most notable development in the run-up has been a string of upward target revisions. Oppenheimer lifted its target to $108 from $95 on October 22, keeping an Outperform rating. Barclays raised its target to $105 from $96 the week prior, also maintaining Overweight. The consensus mean now sits at $97.47, implying modest upside from the current price of $93.02, though most of the bullish activity has come from analysts already constructive on the name rather than fresh upgrades. Citi trimmed its target fractionally to $100 but held its Buy rating, the one outlier in an otherwise upbeat recent run of revisions.

The bull and bear cases reflect a company in transition. Bulls point to the near-doubling of return on capital to 5.32% over the past year and solid taste-segment growth of 6% on a currency-neutral basis as evidence that the restructuring is generating real operational improvement. Bears counter that the divestiture programme is a drag on the top line, with revenue projected to decline roughly 5.56% to around $10.68 billion over the next twelve months as Pharma Solutions and other units roll off. The debate is less about whether IFF is stabilising and more about whether the pace of margin improvement can offset a shrinking revenue base.

Short positioning has reversed course since the last note published on October 21. Short interest climbed 7.25% over the past week to 5.9% of free float, partly unwinding the steady decline described then. That said, the lending market remains relaxed: availability is running at 391%, meaning there are nearly four shares available to borrow for every one currently lent out, well above the 52-week tightest reading of 188% hit in mid-September. Cost to borrow is negligible at 0.43%. Options positioning is mildly more defensive than usual, with the put/call ratio at 0.80, roughly 1.3 standard deviations above its 20-day average, but nowhere near the distress territory of the 52-week high of 1.40. Borrow conditions remain too loose and the short-score too contained (56.7) to read the short-interest uptick as anything more than pre-earnings hedging.

The ownership picture adds one point of interest. Dodge & Cox holds 14.5% of shares and added around 534,000 shares in Q3, while Invesco added over 1.4 million shares in the same period. Director Paul Fribourg made a notable open-market purchase of around 273,500 shares in June at roughly $74, now sitting on a meaningful paper gain as the stock trades at $93.

The November 3 print will test whether IFF's improving returns profile is durable enough to justify the stock's 30-times trailing earnings multiple against a revenue line set to contract.